211 related articles for article (PubMed ID: 23974006)
1. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Yin X; Luistro L; Zhong H; Smith M; Nevins T; Schostack K; Hilton H; Lin TA; Truitt T; Biondi D; Wang X; Packman K; Rosinski J; Berkofsky-Fessler W; Tang JP; Pant S; Geho D; Vega-Harring S; Demario M; Levitsky H; Simcox M
Clin Cancer Res; 2013 Oct; 19(20):5686-98. PubMed ID: 23974006
[TBL] [Abstract][Full Text] [Related]
2. Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Meulendijks D; Lassen UN; Siu LL; Huitema AD; Karanikas V; Mau-Sorensen M; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD; Schellens JH
Clin Cancer Res; 2016 Feb; 22(4):858-67. PubMed ID: 26446946
[TBL] [Abstract][Full Text] [Related]
3. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN; Meulendijks D; Siu LL; Karanikas V; Mau-Sorensen M; Schellens JH; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD
Clin Cancer Res; 2015 Jan; 21(2):258-66. PubMed ID: 25388164
[TBL] [Abstract][Full Text] [Related]
4. TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage.
Kaduka Y; Takeda K; Nakayama M; Kinoshita K; Yagita H; Okumura K
Biochem Biophys Res Commun; 2005 Jun; 331(2):384-90. PubMed ID: 15850771
[TBL] [Abstract][Full Text] [Related]
5. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
[TBL] [Abstract][Full Text] [Related]
6. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases.
Yepes M; Winkles JA
Drug News Perspect; 2006 Dec; 19(10):589-95. PubMed ID: 17299600
[TBL] [Abstract][Full Text] [Related]
8. Development of an Fn14 agonistic antibody as an anti-tumor agent.
Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
[TBL] [Abstract][Full Text] [Related]
9. Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis.
Pettersen I; Baryawno N; Abel F; Bakkelund WH; Zykova SN; Winberg JO; Moens U; Rasmuson A; Kogner P; Johnsen JI; Sveinbjörnsson B
Int J Oncol; 2013 Apr; 42(4):1239-48. PubMed ID: 23443741
[TBL] [Abstract][Full Text] [Related]
10. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.
Culp PA; Choi D; Zhang Y; Yin J; Seto P; Ybarra SE; Su M; Sho M; Steinle R; Wong MH; Evangelista F; Grove J; Cardenas M; James M; Hsi ED; Chao DT; Powers DB; Ramakrishnan V; Dubridge R
Clin Cancer Res; 2010 Jan; 16(2):497-508. PubMed ID: 20068083
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.
Moreno JA; Sastre C; Madrigal-Matute J; Muñoz-García B; Ortega L; Burkly LC; Egido J; Martín-Ventura JL; Blanco-Colio LM
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):612-20. PubMed ID: 23288170
[TBL] [Abstract][Full Text] [Related]
13. TWEAK signals through JAK-STAT to induce tumor cell apoptosis.
Chapman MS; Wu L; Amatucci A; Ho SN; Michaelson JS
Cytokine; 2013 Jan; 61(1):210-7. PubMed ID: 23107828
[TBL] [Abstract][Full Text] [Related]
14. TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells.
Ando T; Ichikawa J; Wako M; Hatsushika K; Watanabe Y; Sakuma M; Tasaka K; Ogawa H; Hamada Y; Yagita H; Nakao A
Arthritis Res Ther; 2006; 8(5):R146. PubMed ID: 16945157
[TBL] [Abstract][Full Text] [Related]
15. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis.
Dohi T; Borodovsky A; Wu P; Shearstone JR; Kawashima R; Runkel L; Rajman L; Dong X; Scott ML; Michaelson JS; Jakubowski A; Burkly LC
Gastroenterology; 2009 Mar; 136(3):912-23. PubMed ID: 19109961
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
19. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Wu KD; Zhou L; Burtrum D; Ludwig DL; Moore MA
Cancer Immunol Immunother; 2007 Mar; 56(3):343-57. PubMed ID: 16832681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
